Use of Dehydrated Amnion/Chorion Membrane (dACM) in a Slow Healing Trauma Wound

Background:

- Allograft skin substitutes are currently approved for reimbursement by Centers for Medicare and Medicaid Services (CMS) and most insurances for:
 - venous leg ulcerations

• diabetic foot ulcers

- Use of allograft skin substitutes not approved for reimbursement for traumatic injury
- May be beneficial for optimal wound healing in traumatic wounds

Aim:

• The aim of this case study is to report the treatment effect of dehydrated amnion/chorion membrane (dACM*) in the treatment of a slow-healing, chronic leg wound secondary to trauma.





Week 1

Presented to the UPMC Passavant Wound Healing Services



Week 7 4.3X9X1.7

Week 1

Dawn Wang MD FACS; Susan Rolniak St John MSN CRNP; Jodi Boory BSN RN CRRN CHRN CWCA OMS **UPMC Wound Healing Services at UPMC Passavant**

Case Study:

- 85 year old female with body mass index of 33.4, peripheral vascular disease, chronic lower leg edema, and warfarin therapy sustained a laceration/hematoma on the middle third of the right lower leg during a low energy fall.
- The original wound measurement: 5 x 15 x 0.1 cm 10 days post injury
- Nine weeks of treatment at outside facility
- Presented to the UPMC Passavant Wound Healing Services with a chronic wound 4.4 x 10.0 x 0.1 cm with a necrotic base
- Ankle brachial index measurements = 0.61
- Wound was debrided of hematoma and devitalized tissue
- Post-debridement 5 X 7.5 X 1.7 cm
- dACM therapy initiated when the wound base was developing granular tissue
- Application protocol of dACM, wound gel, versatel, steri-strip, foam dressing and tubigrip. Kept in place for a week
- 10 weekly dACM per protocol
- Complete wound healing :
- 20 weeks post injury
- 11 weeks after completion of dACM treatment series




Week 10 4.0X6.0X0.9



Week 12 3.6X5.2X0.4



Week 16 0.8X1.3X0.1



Conclusion:


The use of dACM, which consists of extracellular matrix proteins, growth factors, and cytokines, appears to be advantageous in the management of slow-healing trauma wounds. This patient improved with the use of dACM, but more research is needed to evaluate the benefits of dACM in trauma wounds.



Week 17 0.4X0.6X0.1



Week 18 0.2x0.2X0.1



Week 20 HEALED

Services

2030 Mackenzie Way F 724-772-8276

*Nushield^R, Organogenesis, Inc., Canton MA

1 year later HEALED



1 year later HEALED